orchard
therapeutics
receives
ema
prime
designation
treatment
boston
london
globe
newswire
orchard
therapeutics
nasdaq
ortx
global
gene
therapy
leader
today
announced
european
medicines
agency
ema
granted
priority
medicines
prime
designation
investigational
ex
vivo
autologous
hematopoietic
stem
cell
hsc
gene
therapy
development
treatment
mucopolysaccharidosis
type
san
raffaele
telethon
institute
gene
therapy
milan
italy
encouraged
ema
decision
grant
prime
designation
based
initial
clinical
assessment
data
supporting
potential
benefit
hsc
gene
therapy
patients
beyond
current
standard
care
said
anne
chief
regulatory
officer
orchard
look
forward
building
upon
promising
early
data
ongoing
study
plan
initiate
registrational
trial
advance
potential
new
treatment
prime
program
designed
enhance
regulatory
support
eu
development
promising
investigational
medicines
based
early
clinical
data
may
offer
major
therapeutic
advantage
existing
treatments
benefit
patients
without
treatment
options
prime
aims
provide
multiple
benefits
medicines
reach
patients
earlier
enhanced
interaction
early
dialogue
ema
guidance
overall
development
plan
regulatory
strategy
potential
accelerated
assessment
marketing
authorization
application
information
please
visit
ema
website
additional
interim
data
recently
presented
ongoing
clinical
trial
evaluating
safety
efficacy
severe
hurler
subtype
eight
patients
treated
study
completed
enrollment
december
july
patients
followed
minimum
six
months
longest
extending
months
orchard
expects
release
full
results
one
year
initiate
registrational
study
mucopolysaccharidosis
type
rare
inherited
neurometabolic
disease
caused
deficiency
idua
lysosomal
enzyme
required
break
sugar
molecules
called
glycosaminoglycans
also
known
gags
accumulation
gags
across
multiple
organ
systems
results
symptoms
including
neurocognitive
impairment
skeletal
deformity
loss
vision
hearing
cardiovascular
pulmonary
complications
occurs
overall
estimated
frequency
one
every
live
births
three
subtypes
approximately
percent
children
born
severe
subtype
called
hurler
syndrome
rarely
live
past
age
untreated
treatment
options
include
hematopoietic
stem
cell
transplant
chronic
enzyme
replacement
therapy
significant
limitations
though
early
intervention
enzyme
replacement
therapy
shown
delay
prevent
clinical
features
condition
limited
efficacy
neurological
symptoms
investigational
ex
vivo
autologous
hematopoietic
stem
cell
gene
therapy
studied
treatment
orchard
granted
exclusive
worldwide
license
intellectual
property
rights
research
develop
manufacture
commercialize
gene
therapy
program
treatment
developed
san
raffaele
telethon
institute
gene
therapy
milan
italy
orchard
orchard
therapeutics
global
gene
therapy
leader
dedicated
transforming
lives
people
affected
rare
diseases
development
innovative
potentially
curative
gene
therapies
ex
vivo
autologous
gene
therapy
approach
harnesses
power
genetically
modified
blood
stem
cells
seeks
correct
underlying
cause
disease
single
administration
orchard
acquired
gsk
rare
disease
gene
therapy
portfolio
originated
pioneering
collaboration
gsk
san
raffaele
telethon
institute
gene
therapy
milan
italy
orchard
one
deepest
advanced
gene
therapy
product
candidate
pipelines
industry
spanning
multiple
therapeutic
areas
disease
burden
children
families
caregivers
immense
current
treatment
options
limited
exist
orchard
global
headquarters
london
headquarters
boston
information
please
visit
follow
us
twitter
linkedin
availability
information
orchard
investors
others
note
orchard
communicates
investors
public
using
company
website
investor
relations
website
social
media
twitter
linkedin
including
limited
investor
presentations
investor
fact
sheets
securities
exchange
commission
filings
press
releases
public
conference
calls
webcasts
information
orchard
posts
channels
websites
could
deemed
material
information
result
orchard
encourages
investors
media
others
interested
orchard
review
information
posted
channels
including
investor
relations
website
regular
basis
list
channels
may
updated
time
time
orchard
investor
relations
website
may
include
additional
social
media
channels
contents
orchard
website
channels
website
may
accessed
website
channels
shall
deemed
incorporated
reference
filing
securities
act
statements
press
release
contains
certain
statements
orchard
strategy
future
plans
prospects
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
statements
may
identified
words
anticipates
believes
expects
plans
intends
projects
future
similar
expressions
intended
identify
statements
statements
include
express
implied
statements
relating
among
things
orchard
business
strategy
goals
therapeutic
potential
orchard
product
candidates
including
product
candidate
referred
release
orchard
expectations
regarding
timing
clinical
trials
product
candidates
including
product
candidate
referred
release
timing
interactions
regulators
regulatory
submissions
related
ongoing
new
clinical
trials
product
candidates
timing
announcement
clinical
data
product
candidates
likelihood
data
positive
support
clinical
development
regulatory
approval
product
candidates
statements
neither
promises
guarantees
subject
variety
risks
uncertainties
many
beyond
orchard
control
could
cause
actual
results
differ
materially
contemplated
statements
particular
risks
uncertainties
include
without
limitation
severity
impact
pandemic
orchard
business
including
clinical
development
supply
chain
commercial
programs
risk
orchard
realize
anticipated
benefits
new
strategic
plan
expected
cash
savings
associated
plan
risk
one
orchard
product
candidates
including
product
candidate
referred
release
successfully
developed
approved
commercialized
risk
cessation
delay
orchard
ongoing
planned
clinical
trials
risk
orchard
may
successfully
recruit
enroll
sufficient
number
patients
clinical
trials
risk
prior
results
signals
safety
activity
durability
effect
observed
preclinical
studies
clinical
trials
replicated
continue
ongoing
future
studies
trials
involving
orchard
product
candidates
adverse
safety
findings
may
discovered
delay
orchard
regulatory
submissions
failure
obtain
marketing
approval
applicable
regulatory
authorities
orchard
product
candidates
receipt
restricted
marketing
approvals
risk
delays
orchard
ability
commercialize
product
candidates
approved
given
uncertainties
reader
advised
place
undue
reliance
statements
risks
uncertainties
faced
orchard
include
identified
heading
risk
factors
orchard
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
sec
well
subsequent
filings
reports
filed
sec
statements
contained
press
release
reflect
orchard
views
date
hereof
orchard
assume
specifically
disclaims
obligation
publicly
update
revise
statements
whether
result
new
information
future
events
otherwise
except
may
required
law
contacts
investors
renee
leck
director
investor
relations
media
molly
cameron
manager
corporate
communications
media
